Type T non--viral vector and composite medicament containing the same

Abstract

The invention relates to a composite medicine of non-viral vector fused protein TNF alpha m2-SON2-GR and limiting expression bacillus pyocyaneus exotoxin gene killing functional domain high-efficiency mutant type recombinant 5xNFBS-SCP-PEIIImut. In the non-viral vector, the TNF alpha m2 is a strong-efficiency and low-toxicity TNF alpha derivative, SON2 is a DNA combined protein, and GRP is gastrin release peptide; the 5 x NFBS of the toxin gene recombinant is the combined site of NF-kappa B repeatedly cloned for 5 times, SCP is a tumor specificity promoter, and PEIIImut is the bacillus pyocyaneus exotoxin gene killing functional domain high-efficiency mutant type. The non-viral vector can combine and carry the toxin gene recombinant to enter positive cells of a GRP acceptor, but the toxin gene can only be expressed in positive malignant tumor cells of the NF-kappa B<+>SCP <+>GRP acceptor, and further strongly efficient kills the tumor cells insensitive to chemical treatment and radioactive treatment. The non-viral vector can independently kill the positive malignant tumor cells of the GRP acceptor. The invention also relates to application of the composite medicine and the independent non-viral vector in the treatment of the malignant tumor.

Description

technical field [0001] The invention belongs to the field of gene therapy drugs. Specifically, the present invention relates to a composite drug of non-viral vector fusion protein TNFαm2-SON2-GRP and restricted expression of Pseudomonas aeruginosa exotoxin gene killing function domain efficient mutant recombinant 5×NFBS-SCP-PEIIImut. TNFαm2 in non-viral vectors is a potent and low-toxic tumor necrosis factor α (TNFα) derivative, SON2 is a DNA-binding protein, and GRP is a gastrin-releasing peptide. The 5×NFBS on the toxin gene recombinant is the binding site of NF-κB cloned five times, SCP is a tumor-specific promoter, and PEIIImut is a high-efficiency mutant of the Pseudomonas aeruginosa exotoxin gene killing domain. This non-viral vector can combine and carry the above toxin gene recombinant into GRP receptor positive cells, but the toxin gene can only be expressed in NF-κB + SCP + GRP receptor-positive malignant tumor cells are expressed, thereby effectively killing such...

AI Technical Summary

Problems solved by technology

However, they are heterologous toxin proteins of the human body, and there are two problems in their clinical application: one is that their cell killing effect does not have tumor cell specificity, so they can cause serious toxic and side effects to the human body; The source protein has strong immunogenicity, and its introduction into the human blood circulation will not only lead to the rapid generation of antibodies and be neutralized and inactivated, but also cause severe allergic reactions in the human body

There are two outstanding shortcomings of this technical route: one is that the cost of chemically synthesizing peptides is too high, and it is almost impossible to be adopted by industrial development practices; the other is that liposomes have strong toxic side effects of killing cells

Its disadvantages are high cost and toxic side effects

Moreover, the expression of most of its genes with killing function is placed under the drive of constitutive promoters such as pSV40 or pCMV, and under the guidance of ligands or antibodies, functional gene recombinants enter both tumor cells and normal cells, As a result, while killing tumor cells, it also kills normal cells, causing varying degrees of toxic and side effects

Images